Where Will Cameco Stock Be in 5 Years?
Cameco (NYSE: CCJ) isn’t exactly the kind of stock you…
Sell
48
NVAX Quote, Financials, Valuation and Earnings
Last price:
$7.18
Seasonality move
:
14.77%
Day range:
$6.90 - $7.28
52-week range:
$5.01 - $23.86
Dividend yield:
0%
P/E ratio:
2.71x
P/S ratio:
0.98x
P/B ratio:
--
Volume:
6.1M
Avg. volume:
11.6M
1-year change:
-52.42%
Market cap:
$1.2B
Revenue:
$682.2M
EPS (TTM):
$2.65
Analysts' Opinion
-
Consensus RatingNovavax has received a consensus rating of Buy. The company's average rating is a Buy based on 3 Buy ratings, 2 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $14.67, Novavax has an estimated upside of 103.99% from its current price of $7.19.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $7.00 representing 100% downside risk from its current price of $7.19.
Fair Value
-
According to the consensus of 5 analysts, Novavax has 103.99% upside to fair value with a price target of $14.67 per share.
NVAX vs. S&P 500
-
Over the past 5 trading days, Novavax has underperformed the S&P 500 by -0.75% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Novavax does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Novavax has grown year-over-year revenues for 1 quarter straight. In the most recent quarter Novavax reported revenues of $626.3M.
Earnings Growth
-
Novavax has grown year-over-year earnings for 0 quarters straight. In the most recent quarter Novavax reported earnings per share of $2.93.
Enterprise value:
603.2M
EV / Invested capital:
6.38x
Price / LTM sales:
0.98x
EV / EBIT:
1.18x
EV / Revenue:
0.50x
PEG ratio (5yr expected):
--
EV / Free cash flow:
-3.04x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
1.09x
Gross Profit (TTM):
$1.1B
Return On Assets:
30.93%
Net Income Margin (TTM):
39.41%
Return On Equity:
--
Return On Invested Capital:
--
Operating Margin:
82.31%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-03-31 | 2024-03-31 | 2025-03-31 | 2024-03-31 | 2025-03-31 | |
| Income Statement | ||||||
| Revenue | $1.1B | $793.7M | $1.2B | $93.9M | $626.3M | |
| Gross Profit | $174.1M | $424.9M | $1.1B | $34.6M | $612.2M | |
| Operating Income | -$1.2B | -$398.6M | $411.4M | -$144.8M | $515.5M | |
| EBITDA | -$1.1B | -$337.1M | $554.9M | -$129M | $533.9M | |
| Diluted EPS | -$14.37 | -$3.20 | $2.65 | -$1.05 | $2.93 | |
| Period Ending | 2021-03-31 | 2022-03-31 | 2023-03-31 | 2024-03-31 | 2025-03-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $2.2B | $2.3B | $971M | $727.1M | $868M | |
| Total Assets | $2.6B | $2.8B | $1.5B | $1.4B | $1.3B | |
| Current Liabilities | $1.2B | $2.3B | $1.9B | $804.4M | $422.2M | |
| Total Liabilities | $1.6B | $2.8B | $2.4B | $2.2B | $1.4B | |
| Total Equity | $1B | $65.3M | -$895.6M | -$867.1M | -$75.6M | |
| Total Debt | $322.4M | $323.8M | $166.9M | $168.4M | $170.1M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-03-31 | 2024-03-31 | 2025-03-31 | 2024-03-31 | 2025-03-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$653M | -$471.9M | -$189.2M | -$83.6M | -$185.5M | |
| Cash From Investing | -$99.7M | -$42.5M | -$270.1M | -$7.3M | -$73.3M | |
| Cash From Financing | -$189.3M | $364.7M | $247.6M | $5.9M | -$7.1M | |
| Free Cash Flow | -$752.7M | -$514.4M | -$198.2M | -$90.8M | -$187.1M | |
NVAX
Sector
Market Cap
$1.2B
$34.1M
Price % of 52-Week High
30.13%
45.43%
Dividend Yield
0%
0%
Shareholder Yield
-24.74%
-0.66%
1-Year Price Total Return
-52.42%
-39.29%
Beta (5-Year)
3.210
0.653
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Sell
Level
$7.32
200-day SMA
Sell
Level
$9.11
Bollinger Bands (100)
Sell
Level
6.45 - 8.65
Chaikin Money Flow
Sell
Level
-825.8M
20-day SMA
Buy
Level
$6.69
Relative Strength Index (RSI14)
Buy
Level
54.29
ADX Line
Buy
Level
18.64
Williams %R
Neutral
Level
-53.3557
50-day SMA
Buy
Level
$6.67
MACD (12, 26)
Buy
Level
0.18
25-day Aroon Oscillator
Buy
Level
24
On Balance Volume
Neutral
Level
1.3B
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (-4.0527)
Sell
CA Score
(Annual)
Level (-4.8552)
Buy
Beneish M-Score
(Annual)
Level (-3.4236)
Buy
Momentum Score
Level (9)
Sell
Ohlson Score
Level (7.3742)
Buy
Piotroski F Score
(Annual)
Level (6)
Buy
Quality Ratio Score
Level (5)
Sell
Fundamental Score
Level (3)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases. It works together with its wholly owned Swedish subsidiary to produce vaccine candidates to respond to both known and emerging disease threats. The company believes its vaccine technology has the potential to be applied broadly to a wide variety of human infectious diseases. The company manages its business as one operating segment, the development and commercialization of vaccines. The company generates maximum revenue from the United States.
Stock Forecast FAQ
In the current month, NVAX has received 3 Buy ratings 2 Hold ratings, and 0 Sell ratings. The NVAX average analyst price target in the past 3 months is $14.67.
-
Where Will Novavax Stock Be In 1 Year?
According to analysts, the consensus estimate is that Novavax share price will rise to $14.67 per share over the next 12 months.
-
What Do Analysts Say About Novavax?
Analysts are divided on their view about Novavax share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Novavax is a Sell and believe this share price will drop from its current level to $7.00.
-
What Is Novavax's Price Target?
The price target for Novavax over the next 1-year time period is forecast to be $14.67 according to 5 Wall Street analysts, 3 of them rate the stock a Buy, 0 rate the stock a Sell, and 2 analysts rate the stock a Hold.
-
Is NVAX A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Novavax is a Buy. 3 of 5 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of NVAX?
You can purchase shares of Novavax via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Novavax shares.
-
What Is The Novavax Share Price Today?
Novavax was last trading at $7.18 per share. This represents the most recent stock quote for Novavax. Yesterday, Novavax closed at $7.19 per share.
-
How To Buy Novavax Stock Online?
In order to purchase Novavax stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Microsoft Stock Outlook, Azure & AI as Drivers of Long-Term Growth
Microsoft (NASDAQ:MSFT) has been among the top growth stocks of…
Is Tesla Stock Overvalued or a Buy for the Next Decade?
Shares of EV major Tesla (NASDAQ:TSLA) have experienced extreme volatility…
Stock Ideas
Buy
67
Is MSFT Stock a Buy?
Market Cap: $3.4T
P/E Ratio: 39x
Buy
70
Is NVDA Stock a Buy?
Market Cap: $3.4T
P/E Ratio: 47x
Sell
39
Is AAPL Stock a Buy?
Market Cap: $3T
P/E Ratio: 33x
Alerts
Buy
84
SBET alert for May 30
SharpLink Gaming [SBET] is up 26.92% over the past day.
Buy
55
RGC alert for May 30
Regencell Bioscience Holdings [RGC] is up 23.22% over the past day.
Buy
73
CTEV alert for May 30
Claritev [CTEV] is up 4.31% over the past day.
